SCHEMBL4068596

SCHEMBL4068596

CC(F)(CC[C@H](C[C@H](O)[CH]Cc1ccccc1)C(=O)NCCc1ccccn1)C(N)=O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.42
MEN1 O00255 4/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 2/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
NPY1R P25929 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
REN P00797 1/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
MAPK1 P28482 1/20 0.38
PKM P14618 1/20 0.37
KCNA5 P22460 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071795 1.00 KMT2A (0.44) KMT2ASMN1; SMN2MEN1ALDH1A1HTT
SCHEMBL4067750 0.91 TSHR (0.48) KMT2ASMN1; SMN2MEN1ALDH1A1HTT
SCHEMBL4067483 0.88 RAB9A (0.40) SMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL4068096 0.86 CYP3A4 (0.40) KMT2ASMN1; SMN2MEN1RAB9ANPC1
SCHEMBL4060470 0.85 PLAAT3 (0.41) RAB9ANPC1
SCHEMBL4071319 0.85 ESRRG (0.41) MAPTRAB9ANPC1
SCHEMBL4066973 0.84 HPGD (0.35) ALDH1A1MAPK1
SCHEMBL6675011 0.84 CCR1 (0.43) KMT2AALDH1A1RAB9A
SCHEMBL4070821 0.83 ADAM17 (0.45) SMN1; SMN2RAB9ANPC1
SCHEMBL4060776 0.83 CCR1 (0.37) SMN1; SMN2HTTL3MBTL1CYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966443-B1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER (US) 2009-01-28 EP disclosed
US-20020198207-A1 Novel Hexanoic acid derivatives KATH JOHN CHARLES (US) 2002-12-26 US disclosed
US-6403587-B1 AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND PFIZER INC. 2002-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198207-A1 Novel Hexanoic acid derivatives HCAR3, HCAR1, FFAR1 KMT2A 2539/4885SMN1; SMN2 3291/4885MEN1 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.